These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
130 related items for PubMed ID: 7532608
1. Extracellular iron chelators protect kidney cells from hypoxia/reoxygenation. Paller MS, Hedlund BE. Free Radic Biol Med; 1994 Dec; 17(6):597-603. PubMed ID: 7532608 [Abstract] [Full Text] [Related]
2. Post-hypoxic cellular disintegration in glycine-preserved renal tubules is attenuated by hydroxyl radical scavengers and iron chelators. Moussavian MR, Slotta JE, Kollmar O, Menger MD, Gronow G, Schilling MK. Langenbecks Arch Surg; 2008 May; 393(3):303-10. PubMed ID: 18283485 [Abstract] [Full Text] [Related]
3. The long-acting parenteral iron chelator, hydroxyethyl starch-deferoxamine, fails to protect against alcohol-induced liver injury in rats. Sadrzadeh SM, Hallaway PE, Nanji AA. J Pharmacol Exp Ther; 1997 Feb; 280(2):1038-42. PubMed ID: 9023321 [Abstract] [Full Text] [Related]
5. The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell. Richardson D, Ponka P, Baker E. Cancer Res; 1994 Feb 01; 54(3):685-9. PubMed ID: 8306330 [Abstract] [Full Text] [Related]
7. Conjugation of hydroxyethyl starch to desferrioxamine (DFO) modulates the dual role of DFO in Yersinia enterocolitica infection. Schubert S, Autenrieth IB. Clin Diagn Lab Immunol; 2000 May 01; 7(3):457-62. PubMed ID: 10799461 [Abstract] [Full Text] [Related]
8. Modulation of deferoxamine toxicity and clearance by covalent attachment to biocompatible polymers. Hallaway PE, Eaton JW, Panter SS, Hedlund BE. Proc Natl Acad Sci U S A; 1989 Dec 01; 86(24):10108-12. PubMed ID: 2481311 [Abstract] [Full Text] [Related]
9. Intracellular myoglobin loading worsens H2O2-induced, but not hypoxia/reoxygenation-induced, in vitro proximal tubular injury. Zager RA. Circ Res; 1993 Nov 01; 73(5):926-34. PubMed ID: 8403262 [Abstract] [Full Text] [Related]
11. Alterations of the [59Fe]ferric citrate biodistribution in hyperferremic mice after the administration of pyrophosphate and desferrioxamine. Sawas-Dimopoulou C, Soulpi C. J Pharmacol Exp Ther; 1983 Feb 01; 224(2):415-8. PubMed ID: 6296362 [Abstract] [Full Text] [Related]
14. Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools. Hoyes KP, Porter JB. Br J Haematol; 1993 Oct 01; 85(2):393-400. PubMed ID: 8280612 [Abstract] [Full Text] [Related]
16. Combined mannitol and deferoxamine therapy for myohemoglobinuric renal injury and oxidant tubular stress. Mechanistic and therapeutic implications. Zager RA. J Clin Invest; 1992 Sep 01; 90(3):711-9. PubMed ID: 1325995 [Abstract] [Full Text] [Related]
17. Mode of action of iron (III) chelators as antimalarials. IV. Potentiation of desferal action by benzoyl and isonicotinoyl hydrazone derivatives. Tsafack A, Loyevsky M, Ponka P, Cabantchik ZI. J Lab Clin Med; 1996 Jun 01; 127(6):574-82. PubMed ID: 8648262 [Abstract] [Full Text] [Related]
18. Hydroxyethyl starch deferoxamine, a novel iron chelator, delays diabetes in BB rats. Roza AM, Slakey DP, Pieper GM, Van Ye TM, Moore-Hilton G, Komorowski RA, Johnson CP, Hedlund BE, Adams MB. J Lab Clin Med; 1994 Apr 01; 123(4):556-60. PubMed ID: 7511676 [Abstract] [Full Text] [Related]